NASDAQ
21.07USD
-0.41 (-1.91%)
We have scored 8 news catalysts on Tyra Biosciences, Inc. (TYRA) over the past 12 months. The biggest single-day move next to one of them came Sep 14, 2026, when TYRA closed +13.8%: “Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants”. Coverage across the window leans negative (average ticker sentiment −0.19). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.3B
P/E
—
EPS
—
Beta
0.75
52W range
13.35-40.65
Day range
20.32–21.49
Open
21.01
Prev close
21.48
Volume
625.8K
Avg volume
831.8K
Dividend
0.00
IPO
2021-09-15
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Tyra Biosciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for TYRA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
